Home › NDC Lookup › Ingredients › Lisinopril › 00591-0885-00
Lisinopril 30 mg Tablet, 33,300-count — NDC 00591-0885-00 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Lisinopril 30 mg Tablet, 33,300-count — NDC 0591-0885-00 (Billing 00591-0885-00)

by Actavis Pharma, Inc. · 33300 TABLET in 1 BOX

This is a package of 33,300 tablets of Lisinopril 30 mg Tablet from Actavis Pharma, Inc., marketed since Jul 2002 and currently FDA-listed.

NDC 00591-0885-00
🏷️ FDA NDC (as labeled) 0591-0885-00 billing pads the labeler segment with a zero
This package
Contains33,300-count Pack sizes2 compare ↓
Product page 00591-0885-01 Also comes in: 100 tablets 0591-0885-01
On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Oct 8, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 0591-0885-00 alone.

Record
FDA NDC Directory package listing · Drug for further processing
Code segments
0591 labeler · 0885 product · 00 package
Package marketed since
Jul 1, 2002
Listing certified through
Dec 31, 2026
Barcode (UPC-A, from the NDC)
3 0591088500 7
FDA record last changed
Oct 8, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0591-0885-00
Product NDC 0591-0885
11-digit billing NDC 00591088500
SPL Set ID 3fdfd3c3-b1bd-46a3-a105-218aa6ebb0cd
DEA schedule Non-controlled
Marketing category DRUG FOR FURTHER PROCESSING
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2002-07-01
Dosage form TABLET
Substance LISINOPRIL

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 36100030000324
GPI class Lisinopril
GCN Seq No 041567
GCN 47265
HICL code 000132
Ingredient (HICL) Lisinopril
HIC1 code A
Therapeutic class — broad (HIC1) Cardiovascular System
HIC2 code A4
Therapeutic class — intermediate (HIC2) Antihypertensives
HIC3 code A4D
Therapeutic class — specific (HIC3) Antihypertensives, Ace Inhibitors
AHFS code 24:32.04.00
AHFS class Angiotensin-Converting Enzyme Inhibitors
FDB label name LISINOPRIL 30 MG TABLET
FDB brand name Lisinopril
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 041567
  • GCN: 47265
  • GPI-14 (Medi-Span): 36100030000324
  • HICL (First Databank): 000132
  • AHFS class code: 24:32.04.00
Why two NDCs? The FDA registers this code as 0591-0885-00 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00591-0885-00. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name LISINOPRIL 30 MG TABLET Ingredient Lisinopril
📗 Our plain-language guide HelloPharmacist
  • It lowers high blood pressure and is used as add-on treatment for heart failure. It is also used soon after a heart attack to improve survival. Lowering blood pressure helps reduce...
  • You usually take it by mouth once a day. Tablets can be taken with or without food. Follow your prescriber's directions, because the dose is adjusted to your blood pressure.
  • Headache, dizziness, cough and tiredness are the most common. Stand up slowly if you feel lightheaded. Tell me or your doctor if they bother you or don't go away.
  • Get emergency help for swelling of the face, lips, tongue or throat, or trouble breathing. Call your doctor for fainting, yellow skin or eyes, severe belly pain, or very little uri...
📖 Read our full Lisinopril guide →
1
Nutrient depletion considerations

Lisinopril may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Lisinopril nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eachPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Try another pack size: 100 tablets
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
00591-0885-01 0591-0885-01 Main listing 100 TABLET in 1 BOTTLE, PLASTIC $0.0520 / ea $5.20 2002-07-01 — Active
00591-0885-00 You're viewing this 33300 TABLET in 1 BOX — — — — Active

You're viewing the largest of 2 pack sizes for this product.

This pack shows little to no recent Medicaid volume — the 100 tablets pack carries most fills. See all packs ↓

Pack size FAQ

What quantity is in this package?
This is a 33,300-count package — 33300 tablet in 1 box.
How does this package differ from NDC 00591-0885-01?
Both are Lisinopril 30 mg Tablet — the drug itself is identical. This page's package is the 33,300-count one, while NDC 00591-0885-01 is the 100 tablets package.
What NDC number is used to bill for this package of Lisinopril 30 mg Tablet?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
lisinopril 30 mg 23155-0880-01 Heritage 100 tablets $0.052 AB Availability likely —
Lisinopril 30 mg 31722-0179-01 Camber 100 tablets $0.052 AB Availability likely —
Lisinopril 30 mg 43547-0418-10 Solco 100 tablets $0.052 AB Availability likely —
Lisinopril 30 mg 62135-0644-31 Chartwell 300 tablets $0.052 AB Availability likely —
Lisinopril 30 mg 68001-0336-00 BluePoint 100 tablets $0.052 AB Availability likely —
Lisinopril 30 mg 68180-0982-01 Lupin 100 tablets $0.052 AB Availability likely —
Lisinopril 30 mg 68645-0612-90 Legacy 90 tablets $0.052 AB Availability likely —
lisinopril 30 mg 76282-0421-01 Exelan 100 tablets $0.052 AB Availability likely —
Lisinopril 30 mg 76282-0732-01 Exelan 100 tablets $0.052 AB Availability likely —
Lisinopril 30 mgthis 00591-0885-00 Actavis 33300 tablets — — FDA listed —
Lisinopril 30 mg 00615-8548-39 NCS 30 tablets — AB FDA listed —
Zestril 30 mg 24979-0242-07 Upsher-Smith 90 tablets — AB FDA listed —
Lisinopril 30 mg 43063-0814-01 PD-Rx 100 tablets — AB FDA listed —
Lisinopril 30 mg 43547-0355-03 Solco 30 tablets — AB FDA listed —
Lisinopril 30 mg 50090-2934-00 A-S 30 tablets — AB FDA listed —
Lisinopril 30 mg 50090-3175-00 A-S 30 tablets — AB FDA listed —
Lisinopril 30 mg 65862-0041-00 Aurobindo 100 tablets — — FDA listed —
Lisinopril 30 mg 68071-3043-03 NuCare 30 tablets — AB FDA listed —
Lisinopril 30 mg 70518-2561-00 REMEDYREPACK 30 tablets — AB FDA listed —
Lisinopril 30 mg 71205-0071-30 Proficient 30 tablets — AB FDA listed —
Lisinopril 30 mg 71335-0354-01 Bryant 30 tablets — AB Discontinued —
Lisinopril 30 mg 72865-0212-01 XLCare 100 tablets — AB FDA listed —
Lisinopril 30 mg 76420-0344-00 Asclemed 1000 tablets — AB FDA listed —
Lisinopril 30 mg 82868-0009-30 Northwind 30 tablets — AB FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2002
On the market since
Jul 2002
📍
2026
Currently FDA-listed
24 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color white / blue / yellow
ShapeRound
ImprintWATSON;409
Size10 mm
ScoringNot scored
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Lisinopril inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII O7TSZ97GEP
    A mineral compound that serves as a filler and binding agent in tablets and capsules. It adds bulk to the medicine and helps hold ingredients together during manufacturing.
  • UNII I753WB2F1M
    FD&C Yellow No. 5 is a synthetic yellow colorant approved by the FDA. It is added to medicines to make pills, tablets, or liquids visually distinct and easier to identify.
  • UNII 70097M6I30
    Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
  • UNII 3OWL53L36A
    A natural sugar alcohol derived from seaweed or synthesized in the lab. It's used as a filler to add bulk, a sweetener in sugar-free formulas, and a disintegrant to help tablets break apart in the stomach.
  • UNII ETJ7Z6XBU4
    Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
  • UNII O8232NY3SJ
    A plant-based carbohydrate derived from corn kernels. It acts as a filler to add bulk, a binder to hold ingredients together, and a disintegrant to help the tablet break apart in your stomach for absorption.

6 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerActavis Pharma, Inc.
Labeler code00591
First marketedJul 2002
Product typeDrug For Further Processing
Portfolio324 products on file

More NDCs from Actavis Pharma, Inc. labeler code 00591

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full FDA label FDA SPL

The complete FDA label for this product, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
100 tablets00591-0885-01 176 Rx · $1,194
33300 tablets this page00591-0885-00 No Medicaid data
Drug total (last 4 qtrs): 176 Rx · 6,586 units · $1,194 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Lisinopril (matched by generic name) — the program that covers self-administered drugs. 13 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Lisinopril. CMS lists 3 products for this generic; we show the highest-spend one. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$64.63M
Claims incl. refills
8.5M
Beneficiaries
6.7M
Spend / beneficiary
$9.67
Spend / claim
$7.59
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

About this NDC listing & data coverage

Listed for further processing / repackaging

What "drug for further processing" means

FDA lists this package under the "drug for further processing" marketing category: Actavis Pharma, Inc. supplies it to other companies for further processing or repackaging (blister cards that are later repackaged or co-packaged are a common example). The units themselves are a finished dosage form — which is why pricing or Medicaid data can still appear — but this exact package code may not be the presentation a retail pharmacy dispenses.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Drug For Further Processing". Products approved under an application carry an NDA, ANDA, or BLA number.
Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Actavis Pharma, Inc.. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 1 other package presentation of this same product, including 100 tablets (00591-0885-01). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Actavis Pharma, Inc. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 00591-0862-01 · Actavis 00591-1159-30 · ACTAVIS →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.